Skip to content

Oxytocin vs misoprostol trial

Oxytocin versus Oxytocin with 400µg of Sublingual Misoprostol in Preventing Primary Post Partum Haemorrhage: a Randomised Placebo Controlled Trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202409648302665
Enrollment
252
Registered
2024-09-19
Start date
2016-01-04
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum haemorrhage

Interventions

Sponsors

John Egede
Lead Sponsor
Oliver Ogbuinya
Collaborator

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Parturient at term with singleton pregnancy selected for vaginal delivery Patients who are less than para 4 Patient without perineal laceration after delivery Patients with no bleeding disorder

Exclusion criteria

Exclusion criteria: Grand multiparous patients patients with multiple gestation Patients with Prolonged pregnancy Induced or augmented labour Parturient who had caesarean section

Design outcomes

Primary

MeasureTime frame
1.Estimated postpartum blood loss from delivery of the baby to one hour after delivery 2.The incidence of postpartum haemorrhage (blood loss of 500ml and above) in the immediate postpartum period

Secondary

MeasureTime frame
1. Postpartum drop in haemoglobin after 48 hour of delivery. This was be calculated from the difference between the pre-delivery Hb and the Hb at 48 hours after delivery. 2. The requirement for additional uterotonics 3. The need for blood transfusion 4. The need for additional interventions such as manual removal of placenta 5. Maternal complications and adverse effects

Countries

Nigeria

Contacts

Public ContactJohn Egede

Consultant Obstetrician and Gynaecologist AEFUTHA

egedejohno@gmail.com+2348037797950

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026